The quantification of Aβ1-42 in CSF in combination with total and/or phosphorylated tau protein was recently (together with positron emission tomography and structural magnetic resonance imaging) included in proposed research criteria for the clinical diagnosis of AD [8]. The gene discussed is MAPT; the disease is Alzheimer disease.